Exenatide Extended-Release (Bydureon BCise): A Reference Page With Two Deliberate Gaps

This is a reference page, and it is the one page in this pillar defined as much by what it leaves out as by what it contains.

It is not medical advice. It has not been written or reviewed by a clinician, and it makes no recommendation about whether any medication is appropriate for anybody. It does not tell you how much to take, when to take it, or when to change anything.

What makes it unusual is that the sourcing rule this pillar runs on — publish a number only if a primary label states it — bites here in a way it does not elsewhere. Two of the figures a reader arrives looking for are simply not in the document, and the honest response is to say so rather than to fill the gap from a secondary source.

All figures on this page come from one document: BYDUREON BCISE (exenatide) extended-release injectable suspension, for subcutaneous use — the United States Prescribing Information approved by the FDA, read on DailyMed accessed 1 September 2026. The label records an Initial U.S. Approval of 2005.

Section 12.3 describes the extended-release product's behaviour in terms of concentration over time, clearance and volume of distribution. It does not state an absolute bioavailability for the product, and it does not state a single elimination half-life for it.

Those absences are not an oversight in the label. They follow from what the product is, which the next section explains. Because they are absences, this page carries no half-life figure and no bioavailability figure — not a range, not an approximation, not a value borrowed from a different exenatide product.

Exenatide extended-release is not a solution of drug injected and then cleared. It is a formulation designed to release drug slowly from a depot at the injection site over an extended period.

That creates two different processes happening on very different timescales: the release of drug from the depot, and the clearance of drug once it has reached the circulation. A single number labelled "half-life" cannot describe both, and which one it would describe is ambiguous.

What governs the observed concentration curve for a product like this is the slower process — release — rather than the intrinsic clearance of the molecule. This is why the label characterises the product by how concentrations behave over weeks rather than by a half-life, and it is why a figure invented to make the product fit a half-life-shaped field in a database is a modelling decision rather than a fact about the drug.

Software that draws a concentration curve has to supply such a figure, and an apparent value chosen to make a curve behave can be a defensible engineering choice inside a chart. It is not a labeled value, so none appears on this page.

Section 12.3 states that following initiation of once-weekly administration of the product, a gradual increase in plasma exenatide concentration is observed up to approximately Week 10, with mean plasma exenatide concentrations of approximately 208 pg/mL maintained over weekly dosing intervals, indicating that steady state was achieved.

It further states that approximately 10 weeks after discontinuation of therapy, plasma exenatide concentrations generally fall below the minimal quantifiable concentration of 20 pg/mL.

Taken together those two statements are more informative than a half-life would be. They say that this product takes roughly ten weeks to reach a stable level and roughly ten weeks to clear afterwards — a much longer timescale in both directions than any other medication covered in this pillar.

The label also gives a mean apparent clearance of exenatide of 9.1 L/hour, independent of dose, and reports a mean apparent volume of distribution following subcutaneous administration of a single dose of the immediate-release product of 28.3 L, expected to remain unchanged for the extended-release product.

For somebody keeping a personal record, this is the page's practical content.

A medication that takes around ten weeks to reach steady state is one where early weeks are genuinely not representative of later ones, and where a record covering only the first month describes a period during which levels were still climbing. The same applies in reverse after stopping.

That is a strong argument for keeping a longer record rather than a more detailed one. Fine-grained notes about a single week tell you very little about a product operating on this timescale; a continuous, boring record spanning months tells you and your clinician a great deal more.

None of that is a reason to draw your own conclusions from your record. It is a reason to have one worth showing to somebody qualified to interpret it.

It would be easy to fill the two gaps on this page. Figures for exenatide's half-life circulate widely, and a page that quoted one would look more complete and would probably rank better for it.

The reason not to is that the figures available describe different things. Some describe the immediate-release product, a genuinely different formulation. Some are apparent values back-calculated from the extended-release concentration curve, which is a model output rather than a measurement. Presenting either as "the half-life of exenatide extended-release", attributed to an FDA label that does not contain it, would be a fabricated citation.

On a health page a fabricated citation is worse than a gap, because a gap is visible and a false attribution is not. So the gap stays, labelled as a gap, with an explanation of what is missing and why.

GLP-1 Tracker records what you enter: the date of each dose you log, the injection site you noted, weight and BMI entries added over time, meals captured through the photo scan with calories, protein and fiber estimated, and notes about how a week went.

For a product operating on a ten-week timescale, the value of that is continuity rather than precision. What is worth having is a record that spans long enough to show the period the label describes, which memory reliably fails to reconstruct.

What the app does not do is decide anything. It does not evaluate whether your routine is working, it does not flag anything as clinically significant, and it does not generate schedules.

GLP-1 Tracker includes an educational medication-level view that draws a curve from logged doses and a published half-life figure.

For this medication that curve rests on an assumption the label does not supply, because the label states no half-life for the extended-release product. Whatever the chart draws for it is therefore a modelled approximation of a depot-release process, not a rendering of a labeled value.

That makes it the weakest illustration in the app, and it is worth saying plainly rather than leaving a reader to assume every curve has equal standing. It remains useful for one thing only: conveying that this product's timescale is long. It is not a measurement, not a blood level, and not a clinical reading, and it should never influence a dose.